Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:ABIO

ARCA biopharma (ABIO) Stock Price, News & Analysis

ARCA biopharma logo

About ARCA biopharma Stock (NASDAQ:ABIO)

Key Stats

Today's Range
N/A
50-Day Range
$2.40
$599.04
52-Week Range
N/A
Volume
290,800 shs
Average Volume
607,995 shs
Market Capitalization
$34.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Receive ABIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCA biopharma and its competitors with MarketBeat's FREE daily newsletter.

ABIO Stock News Headlines

This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
FMR LLC Acquires New Stake in ARCA biopharma Inc
See More Headlines

ABIO Stock Analysis - Frequently Asked Questions

ARCA biopharma, Inc. (NASDAQ:ABIO) announced its earnings results on Wednesday, August, 4th. The biopharmaceutical company reported ($48.96) earnings per share for the quarter, beating the consensus estimate of ($341.28) by $292.32.

ARCA biopharma shares reverse split on Tuesday, September 3rd 2024. The 1-12 reverse split was announced on Friday, August 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that ARCA biopharma investors own include Block (SQ), Digital Turbine (APPS), Vuzix (VUZI), Canoo (GOEV), Palantir Technologies (PLTR), ChargePoint (CHPT) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
8/04/2021
Dividend Payable
8/28/2024
Ex-Dividend for 8/28 Dividend
8/29/2024
Today
11/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ABIO
Employees
6
Year Founded
N/A

Profitability

Net Income
$-5,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.25 per share

Miscellaneous

Free Float
10,024,000
Market Cap
$34.82 million
Optionable
Optionable
Beta
0.91
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:ABIO) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners